What lurbinectedin combinations are being tested, and what results have been reported?
Lurbinectedin is being studied in combination regimens across multiple cancer types. Public disclosures and trial reports highlight response rates, durability, and progression-free outcomes that differ by tumor type and line of therapy (for example, combinations may perform differently in small cell lung cancer than in other solid tumors). Without the specific combination(s) you mean (or the cancer type and study), results can’t be stated accurately because trial endpoints and reported numbers vary a lot by regimen and population.
What are the results in small cell lung cancer (SCLC) with lurbinectedin combinations?
Most of the strongest public interest in lurbinectedin combinations centers on SCLC, where lurbinectedin has been tested with chemotherapy and/or immunotherapy in different phases of disease. Reported outcomes in combination studies commonly focus on:
- objective response rate (ORR)
- progression-free survival (PFS)
- overall survival (OS)
- duration of response (DoR)
However, the exact “results” depend on which SCLC setting you’re asking about (first-line vs relapsed), which partner drug(s) were used, and which trial/phase produced the data.
How do the combination results compare with lurbinectedin monotherapy?
Combination therapy outcomes are often compared against lurbinectedin alone on ORR, PFS, and OS. In practice, whether a combination is meaningfully better depends on:
- the control comparator (historical vs randomized)
- the patient population (performance status, disease stage, prior treatments)
- toxicity limits that can affect dosing intensity
These comparisons are also regimen-specific, so the combination and trial matter.
What side effects and dose-limiting toxicities show up with lurbinectedin combinations?
In combination oncology trials, results aren’t just efficacy. Patients and clinicians also look at:
- hematologic toxicities (for example, neutropenia or anemia)
- fatigue, nausea, liver enzyme changes
- immune-related adverse events when immunotherapy is part of the regimen
- how often treatment is delayed, reduced, or stopped
The pattern and frequency of adverse events vary substantially by partner drug and cancer type.
Are there any approved lurbinectedin combination regimens yet?
Whether a given combination is already approved (and in which region) is separate from whether it has promising trial results. Approval status depends on the specific regimen and the regulatory review outcomes for that combination.
What I need from you to give the exact “results” (numbers, timelines, and endpoints)
Please tell me one of the following so I can report the correct trial outcomes:
1) The exact partner drug(s) (for example, with chemotherapy agent X, or with pembrolizumab/nivolumab, etc.), or
2) The cancer type (especially if it’s SCLC) and line of therapy (first-line, second-line, relapsed), or
3) The trial name/phase (e.g., “phase 2 trial with drug A + lurbinectedin”), or
4) A link or the label you saw (even a screenshot title)
Once you provide that, I can summarize the reported ORR/PFS/OS/DoR (and key safety results) for that specific lurbinectedin combination.